CompletedNCT01192867
Official study titleA Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
This study has finished and is no longer accepting participants.
In AustraliaSchizophreniaMedication studyAges 18+
- Countries
- Australia, United States, France, + 11 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01235520
What is this study about?Researchers compared RO4917838 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
In AustraliaSchizophreniaMedication studyAges 18+
- Countries
- Australia, United States, France, + 11 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT00420823
Official study titleA 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.
This study has finished and is no longer accepting participants.
In AustraliaSchizophreniaMedication studyAges 18–25
- Countries
- Australia
- Sponsor
- Melbourne Health
CompletedACTRN12614000429651
Official study titleA Cross-Sectional, Case-Control Study of the Physical Health Status of Vietnam Veterans with and without Post-Traumatic Stress Disorder (PTSD) and Investigation of Genetics of PTSD.
This study has finished and is no longer accepting participants.
In AustraliaPTSDObservational study
- Countries
- Australia
- Sponsor
- Returned Services League (RSL) Queensland
CompletedACTRN12622001535763
Official study titleA study of the psychological, cognitive and physiological effects of Psychedelic Medicines on healthy individuals (ASSESS)
This study has finished and is no longer accepting participants.
In AustraliaMental healthInterventional studyAges 21–70
- Countries
- Australia
- Sponsor
- Monarch Mental Health Group
CompletedNCT00763230
Official study titleA Sham-controlled Study of Transcranial Direct Current Stimulation (tDCS) as a Treatment for Depression
This study has finished and is no longer accepting participants.
In AustraliaDepression, BipolarityDevice studyAges 18–75
- Countries
- Australia
- Sponsor
- The University of New South Wales
CompletedACTRN12617000060347
Official study titleRandomised Controlled Trail testing the effectiveness of an Ecological Momentary Intervention (EMI) in adults with social anxiety symptoms
This study has finished and is no longer accepting participants.
Remote / onlineAnxiety, DepressionInterventional studyAges 18+
- Countries
- Australia
- Sponsor
- Australian National University
CompletedNCT04292197
Official study titleA Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers
This study has finished and is no longer accepting participants.
In AustraliaAddictionMedication studyAges 18–55
- Countries
- Australia
- Sponsor
- Definium Therapeutics US, Inc.
CompletedNCT06524830
Official study titleA Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Repeated Doses of VLS-01 Buccal Film in Participants With Treatment Resistant Depression
This study has finished and is no longer accepting participants.
In AustraliaDepressionMedication studyAges 18–65
- Countries
- Australia, United States, Canada, + 1 other
- Sponsor
- atai Therapeutics, Inc.
CompletedACTRN12621000160831
Official study titleA Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of GRX-917 in Healthy Adult Subjects
This study has finished and is no longer accepting participants.
In AustraliaAnxietyInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- Gaba Therapeutics Australia Pty Ltd a subsidiary of Gaba Therapeutics, Inc